Many rare disease drugs rely on just one trial for approval, FDA authors find

New research published by FDA authors found that 67% of non-oncologic rare disease marketing applications approved between 2020 and 2023 used only one clinical trial plus confirmatory evidence to demonstrate effectiveness. The law defines "substantial ...